Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

56.95EUR
17 May 2019
Change (% chg)

€-0.34 (-0.59%)
Prev Close
€57.29
Open
€57.15
Day's High
€57.24
Day's Low
€56.31
Volume
3,323,031
Avg. Vol
3,457,097
52-wk High
€103.74
52-wk Low
€53.65

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 1.09
Market Cap(Mil.): €53,108.84
Shares Outstanding(Mil.): 932.55
Dividend: 2.80
Yield (%): 4.92

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 53.24 54.03 55.51
EPS (TTM): 1.07 -- --
ROI: 1.19 11.89 11.59
ROE: 2.30 13.19 16.33

Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles

NEW YORK Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk.

May 16 2019

Bayer confident of appeals of glyphosate weed killer court defeats: executive

NEW YORK Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday, amid a steep selloff of the company's shares this week.

May 16 2019

UPDATE 1-Bayer confident of appeals of glyphosate weed killer court defeats -executive

NEW YORK, May 16 Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday, amid a steep selloff of the company's shares this week.

May 16 2019

Bayer is confident of appeals of glyphosate court decisions -executive

NEW YORK, May 16 Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday.

May 16 2019

Bayer nears seven-year low after $2 billion award in Roundup trial

Frankfurt Bayer shares fell by as much as 5 percent on Tuesday after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations its Roundup weed killer causes cancer. | Video

May 14 2019

Factbox: More Roundup trials, appeals in store for Bayer after $2 billion verdict

Bayer shares continued to fall on Tuesday after a California jury on Monday awarded more than $2 billion in damages to a couple who alleged that the company's glyphosate-based weed killer Roundup caused their cancers.

May 14 2019

California jury hits Bayer with $2 billion award in Roundup cancer trial

A California jury on Monday awarded more than $2 billion to a couple who claimed Bayer AG's glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation over the chemical. | Video

May 14 2019

UPDATE 3-Bayer nears 7-year low after $2 bln award in Roundup trial

* Is appealing two previous lost cases (Adds share price graphic, updates shares)

May 14 2019

Bayer stock seen at lowest in nearly 7 years after $2 bln award in Roundup trial

Frankfurt, May 14 Shares in Bayer were down 6.8 percent in early trade on Tuesday after a jury awarded more than $2 billion to a California couple in the largest U.S. jury verdict against the company over allegations its Roundup weed killer causes cancer.

May 14 2019

UPDATE 5-California jury hits Bayer with $2 bln award in Roundup cancer trial

May 13 A California jury on Monday awarded more than $2 billion to a couple who claimed Bayer AG's glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation over the chemical.

May 13 2019

Earnings vs. Estimates